Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
VIVEVE MEDICAL, INC. (VIVE)
|
Add to portfolio |
|
|
|
| Price: |
$3.00
| | Metrics |
| OS: |
10.7
|
M
| |
-2376
|
% ROE
|
| Market cap: |
$32.2
|
M
| |
|
|
|
Net cash:
|
|
| |
|
|
|
EV:
|
$32.2
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($20.5)
|
M
| |
|
|
|
EBIT
|
($21.3)
|
M
| |
|
|
| EPS |
($2.68)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 6.4 | 5.5 | 6.6 | 18.5 | 15.3 | 7.1 | 1.4 | 0.1 |
| Revenue growth | 17.3% | -16.6% | -64.5% | 21.1% | 114.1% | 393.5% | 1507.8% | -40.8% |
| Cost of goods sold | 5.8 | 5.2 | 5.6 | 11.2 | 7.8 | 4.6 | 1.0 | 0.1 |
| Gross profit | 0.6 | 0.3 | 1.0 | 7.3 | 7.4 | 2.5 | 0.5 | 0.0 |
| Gross margin | 9.6% | 5.4% | 15.5% | 39.5% | 48.7% | 35.4% | 31.9% | 44.4% |
| Selling, general and administrative | 12.5 | 13.7 | 22.4 | 38.7 | 28.8 | 12.9 | 7.5 | 4.3 |
| Research and development | 9.7 | 5.1 | 8.6 | 13.6 | 12.3 | 8.4 | 5.0 | 1.4 |
| EBIT | -21.8 | -18.9 | -30.6 | -45.6 | -33.7 | -18.7 | -12.0 | -5.7 |
| EBIT margin | -339.4% | -344.6% | -465.4% | -246.4% | -220.6% | -261.9% | -828.6% | -6291.1% |
| Pre-tax income | -21.8 | -21.5 | -41.9 | -49.3 | -37.0 | -20.1 | -12.4 | -6.2 |
| Income taxes | 0.0 | 0.4 | 0.6 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | | | | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -26.7 | -26.1 | -42.9 | -50.0 | -37.0 | -20.1 | -12.4 | -6.2 |
| Net margin | -415.8% | -475.7% | -653.4% | -269.9% | -241.8% | -281.6% | -858.7% | -6866.7% |
| |
| Diluted EPS | ($2.65) | ($16.56) | ($343.84) | ($160.92) | ($2.11) | ($2.18) | ($2.47) | ($1.27) |
| Shares outstanding (diluted) | 10.1 | 1.6 | 0.1 | 0.3 | 17.5 | 9.2 | 5.0 | 4.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|